Warning Letter — PLZ Corp
The FDA issued a Warning Letter to PLZ Corp following an evaluation by the Center for Drug Evaluation and Research (CDER). The document cites specific compliance failures related to drug manufacturing standards.
This affects PLZ Corp, its quality management personnel, and potentially any downstream partners or clients relying on their drug manufacturing or packaging services.
A Warning Letter from CDER indicates that the agency has identified significant violations of Current Good Manufacturing Practice (cGMP) regulations. Professional interpretation suggests this may result in a recommendation to withhold approval of new applications or supplements until the violations are corrected. This action signals that the facility's quality system is currently insufficient to ensure the safety, identity, strength, quality, and purity of the drugs produced.
Quality and regulatory teams should perform a retrospective audit of manufacturing site compliance to ensure all drug production processes align with cGMP and CDER requirements. Companies utilizing contract manufacturers should verify that all partners maintain current, compliant registrations and adhere to validated manufacturing protocols as outlined in FDA regulations.
FDA Warning Letter issued to: PLZ Corp. 06/02/2026 — Center for Drug Evaluation and Research (CDER). Source: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/plz-corp-721140-06022026
Open in openFDA / FDA.gov